About ISofol Medical AB (publ)
Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy. I
Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy. I
Company Highlights
Year Founded
2008
Employees
9
Location (HQ)
SWE
Monthly Website Visitors
7.5K
Key Metrics
Senior Hires
Name | Linkedin Profile | Position | Date Joined |
---|---|---|---|
John Doe | https://www.linkedin.com/in/johndoe | CEO | CEO |
Jane Doe | https://www.linkedin.com/in/janedoe | CTO | CTO |
John Smith | https://www.linkedin.com/in/johnsmith | CFO | CFO |
Jane Smith | https://www.linkedin.com/in/janesmith | COO | COO |